Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory CLL”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT00963495
What this trial is testing

Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphocytic LeukemiaChronic Lymphocytic Leukemia+4 more
University Health Network, Toronto 11
Testing effectiveness (Phase 2)Study completedNCT00975975
What this trial is testing

Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer

Who this might be right for
Acute Myelogenous LeukemiaAcute Lymphocytic LeukemiaChronic Myelogenous Leukemia+8 more
Indiana University 17
Not applicableNot Yet RecruitingNCT07710781
What this trial is testing

Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies

Who this might be right for
Hematologic MalignancyAcute LeukemiaAcute Lymphoblastic Leukemia+9 more
Ossium Health, Inc. 300
Testing effectiveness (Phase 2)UnknownNCT04271800
What this trial is testing

Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Who this might be right for
LeukemiaLymphomaLeukemia, B-Cell+1 more
Chongqing Precision Biotech Co., Ltd 40
Testing effectiveness (Phase 2)Ended earlyNCT01116232
What this trial is testing

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+5 more
Barbara Ann Karmanos Cancer Institute 4
Testing effectiveness (Phase 2)Study completedNCT00274963
What this trial is testing

Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Who this might be right for
Chronic Lymphocytic Leukemia
German CLL Study Group 60
Testing effectiveness (Phase 2)Study completedNCT01515176
What this trial is testing

Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia

Who this might be right for
Chronic Lymphocytic LeukemiaProlymphocytic LeukemiaRecurrent Small Lymphocytic Lymphoma+1 more
National Cancer Institute (NCI) 36
Testing effectiveness (Phase 2)Study completedNCT00049413
What this trial is testing

Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma

Who this might be right for
LeukemiaLymphoma
Hoag Memorial Hospital Presbyterian
Testing effectiveness (Phase 2)Study completedNCT02005289
What this trial is testing

Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL

Who this might be right for
Contiguous Stage II Small Lymphocytic LymphomaNoncontiguous Stage II Small Lymphocytic LymphomaProlymphocytic Leukemia+9 more
Ohio State University Comprehensive Cancer Center 41
Testing effectiveness (Phase 2)Looking for participantsNCT07523555
What this trial is testing

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLLRelapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia+4 more
Beijing Biotech 96
Testing effectiveness (Phase 2)Study completedNCT03010358
What this trial is testing

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

Who this might be right for
AnemiaB-Cell Prolymphocytic LeukemiaGrade 1 Follicular Lymphoma+11 more
Alexey Danilov, MD 24
Not applicableEnded earlyNCT03050190
What this trial is testing

A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies

Who this might be right for
B-cell Malignancies
Shenzhen Geno-Immune Medical Institute 200
Testing effectiveness (Phase 2)Study completedNCT02071225
What this trial is testing

A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia

Who this might be right for
Chronic Lymphocytic Leukemia
Hoffmann-La Roche 72
Testing effectiveness (Phase 2)Ended earlyNCT01799889
What this trial is testing

Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Chronic Lymphocytic LeukemiaMantle Cell LymphomaDiffuse Large B-cell Lymphoma+2 more
Gilead Sciences 326
Not applicableEnded earlyNCT00904514
What this trial is testing

Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 241
Early research (Phase 1)Study completedNCT00040950
What this trial is testing

Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Jonsson Comprehensive Cancer Center
Testing effectiveness (Phase 2)WithdrawnNCT01131247
What this trial is testing

PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab

Who this might be right for
Chronic Lymphocytic Leukemia (CLL)
Nevada Cancer Institute 37
Testing effectiveness (Phase 2)Study completedNCT04883749
What this trial is testing

Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL

Who this might be right for
Chronic Lymphoid Leukemia
German CLL Study Group 53
Testing effectiveness (Phase 2)Ended earlyNCT04730349
What this trial is testing

Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

Who this might be right for
EpendymomaEwing SarcomaHigh-grade Glioma+7 more
Bristol-Myers Squibb 15
Testing effectiveness (Phase 2)Looking for participantsNCT04941716
What this trial is testing

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

Who this might be right for
Recurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia+1 more
Fred Hutchinson Cancer Center 20
Next Page